跳至主要内容
临床试验/NL-OMON55390
NL-OMON55390已完成2 期

Study A: A placebo-controlled crossover study to assess safety of intranasal administration of palivizumab Study B: Effect of intranasal administration of palivizumab on respiratory syncytial virus-associated infection - a double-blind randomized controlled trial - Narsyn: Nasal administration of palivizumab to prevent RSV infection

niversitair Medisch Centrum Utrecht0 个研究点目标入组 408 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
408

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
2 至 99(—)

入选标准

  • Study A: Healthy adults 18-60 years of age
  • Study B: 32-35 weeks gestational age with at least one brother or sister and
  • less than 6 months old at the start of the RSV season

排除标准

  • Study A: Nasal obstruction, immunocompromised, respiratory symptoms or serious
  • infection 4 weeks before study start, nasal surgery
  • Study B: known congenital heart disease, serious congenital disease, Down

研究者

发起方
niversitair Medisch Centrum Utrecht

相似试验